The search for and potential therapeutic applications of chemical inhibitors of cyclin-dependent kinases;Inhibiteurs chimiques des kinases dependantes des cyclines:Recherche et applications therapeutiques potentielles

Medecine/Sciences

Volumn 15, Issue 4, 1999, Pages 496-503

  Borgne, Annie ^a,b   Meijer, Laurent ^c,d  

^a Assoc pour la Rech sur le Cancer   (France)

^b Imperial Cancer Research Fund   (France)

^c CNRS   (France)

^d STATION BIOLOGIQUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR;

ALZHEIMER DISEASE; ANGIOGENESIS; APOPTOSIS; ATHEROSCLEROSIS; CANCER CHEMOTHERAPY; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL DIVISION; CELL PROLIFERATION; CRYSTALLIZATION; CYTOMEGALOVIRUS INFECTION; GLOMERULONEPHRITIS; HERPES; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MITOSIS INHIBITION; MOLECULAR INTERACTION; NERVE CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLASMODIUM; PSORIASIS; RESTENOSIS; REVIEW; TOXOPLASMA; TRANSCRIPTION REGULATION; TRYPANOSOMA;

CYTOMEGALOVIRUS; HERPES; HUMAN IMMUNODEFICIENCY VIRUS; TOXOPLASMA; TRYPANOSOMA;

EID: 0033005706     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.4267/10608/1375     Document Type: Review

References (45)

1. Morgan D. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 1997; 13: 261-91.
2. Wolowiec D, French M. Kinases dépendantes des cyclines: rôle biologique et implications dans la pathologie humaine. Med Sci 1996; 12: 165-73.
3. Darhon JM, Fesquet D, Cavadore JC. De nouveaux régulateurs du cycle cellulaire: les protéines modulatrices des complexes cdk-cyclines. Med Sci 1995; 11: 349-56.
4. Imahori K, Uchida T. Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. J Biochem 1997; 121: 179-88.
5. Kamb A. Cyclin-dependent kinase inhibitors and human cancer. In: Vogt PK, Reed SI, eds. Cyclin dependent kinase (cdk) inhibitors. Berlin: Springer Verlag, 1998: 139-48.
6. Meijer L. Chemical inhibitors of cyclin-dependent kinases. Trends Cell Biol 1996; 6: 393-7.
7. Meijer L, Kim SH. Chemical inhibitors of cyclin-dependent kinases. Cell cycle control. Meth Enzymol 1997; 283: 113-28.
8. Vesely J, Havlicek L, Strnad M, et al. Inhibition of cyclin-dependent kinases by purine derivatives. Eur J Biochem 1994; 224: 771-86.
9. De Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, Kim, SH. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem 1997; 243: 518-26.
10. Meijer L, Borgne A, Mulner O, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997; 243: 527-36.
11. Gray N, Thunnissen AM, Kwon S, et al. Exploiting chemical libraries, structure, and genomics in the search for new kinase inhibitors. Science 1998; 281: 533-8.
12. Brooks EE, Gray NS, Joly A, et al. CVT-313, a specific and potent inhibitor of CDK2 that pevents neointimal proliferation. J Biol Chem 1997; 272: 29207-11.
13. Park SG, Cheon JY, Lee YH, et al. A specific inhibitor of cyclin-dependent protein kinases, CDC2 and CDK2. Mol Cells 1996; 6: 679-83.
14. Sedlacek HH, Czech J, Naik R, et al. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int J Oncol 1996; 9: 1143-68.
15. Zimmermann J. Pharmacologically active pyrimidine derivatives and processes for the preparation thereof. Bâle: PCT Ciba-Geigy, 1995: WO 95/09853.
16. Ruetz S, Woods-Cook K, Solf R, Meyer T, Zimmermann J, Fabbro D. Effect of CGP60474 on cyclin dependent kinase (cdks), cell cycle proliferation and onset of apoptosis in normal and transformed cells. Proc Am Assoc Cancer Res 1998; 39: 558.
17. Hoessel R, Leclerc S, Endicott J, et al. Indirubin, the active constituent of the Chinese anti-leukemia traditional medicine recipe Danggui Longhui Wan, inhibits cyclin-dependent kinases. Nat Cell Biol 1999 (sous presse).
18. Schultz C, Link A, Leost M, et al. The paullones, a series of cyclin dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibitor, and in vitro antitumor activity. J Med Chem 1999 (sous presse).
19. Kitagawa M, Okabe T, Ogino H, et al. Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase. Oncogene 1993; 8: 2425-32.
20. Legraverend M, Ludwig O, Bisagni E, Leclerc S, Meijer L. Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases. Bioorg Med Chem Lett 1998; 8: 793-8.
21. Schow SR, Mackman RL, Blum CL, et al. Synthesis and activity of 2,6,9-trisubstituted purines. Bioorg Med Chem Lett 1997; 7: 2697-702.
22. Schulze-Gahmen U, Brandsen J, Jones HD, et al. Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins Struct Funct Genet 1995; 22: 378-91.
23. De Azevedo WF, Mueller-Dieckmann HJ, Schultze-Gahmen U, Worland PJ, Sausville E, Kim SH. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci USA 1996; 93: 2735-40.
24. Lawrie AM, Noble ME, Tunnah P, Brown NR, Johnson LN, Endicott JA. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2. Nat Struct Biol 1997; 4: 796-800.
25. Kaur G, Stetler-Stevenson M, Sebers S, et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst 1992; 84: 1736-40.
26. Abraham RT, Acquarone M, Andersen A, et al. Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biol Cell 1995; 83: 105-20.
27. Bible KC, Kaufmann SH. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 1996; 56: 4856-61.
28. Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 1996; 56: 2973-8.
29. Nishio K, Ishida T, Arioka H, et al. Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines. Anticancer Res 1996; 16: 3387-96.
30. König A, Schwartz GK, Mohammad RM, Al-Katib A, Gabrilove JL. The novel cyclin-dependent kinase inhibitor flavopiridiol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 1997; 90: 4307-12.
31. Schutte B, Nieland L, van Engeland M, Henfling MER, Meijer L, Ramaekers FCS. The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics. Exp Cell Res 1997; 236: 4-15.
32. Rudolph B, Saffrich R, Zwicker J, et al. Activation of cyclin-dependent kinases by Myc mediates induction of cyclin A, but not apoptosis. EMBO J 1996; 15: 3065-76.
33. Ongkeko W, Ferguson DJP, Harris AL, Norbury C. Inactivation of cdc2 increases the level of apoptosis induced by DNA damage. J Cell Sci 1995; 108: 2897-904.
34. Shibata Y, Nishimura S, Okuyama A, Nakamura T. p53-independent induction of apoptosis by cyclin-dependent kinase inhibition Cell Growth Diff 1996; 7: 887-91.
35. Schwartz GK, Farsi K, Maslak P, Kelsen DP, Spriggs D. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. Clin Cancer Res 1997; 3: 1467-72.
36. Van Engeland M, Kuijpers HJH, Ramaekers FCS, Reutelingsperger CPM, Schutte B. Plasma membrane alterations and cytoskeletal changes in apoptosis. Exp Cell Res 1997; 235: 421-30.
37. Arguello F, Alexander M, Sterry JA, et al. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 1998; 91: 2482-90.
38. Brüsselbach S, Nettelbeck DM, Sedlacek HH, Müller R. Cell cycle-independent induction of apoptosis by the anti-tumor drug flavopiridol in endothelial cells. Int J Cancer 1999 (sous presse).
39. Park DS, Farinelli SE, Greene LA. Inhibitors of cyclin-dependent kinases promote survival of post-mitotic neuronally differentiated PC12 cells and sympathetic neurons. J Biol Chem 1996; 271: 8161-9.
40. Gil-Gomez G, Berns A, Brady HJM. A link between cell cycle and cell death: Bax and Bcl-2 modulate cdk2 activation during thymocyte apoptosis. EMBO J 1998; 17: 7209-18.
41. Senderowicz A, Headlee D, Stinson SF, et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 1998; 16: 1-17.
42. Pippin JW, Qu Q, Meijer L, Shankland SJ. Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with roscovitine, a novel CDK2 antagonist. J Clin Invest 1997; 100: 2512-20.
43. Bresnahan WA, Boldogh I, Chi P, Thompson EA, Albrecht T. Inhibition of cellular cdk2 activity blocks human cytomegalovirus replication. Virology 1997; 231: 239-47.
44. Mancebo HSY, Lee G, Flygare J, et al. P-TEFβ kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev 1997; 11: 2633-44.
45. Schang LM, Phillips J, Schaffer PA. Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription. J Virol 1998; 72: 5626-37.